Taiwanese biotech firms are aggressively expanding overseas to bypass tariff barriers and capture burgeoning demand for infectious disease management and smart diagnostics.

• Adimmune & Enimmune: Adimmune targets a 60% revenue share from CDMO services within three years. Meanwhile, Enimmune is filing for Enterovirus vaccine licenses in Vietnam and Thailand, while seeking a $100 million market share for its Dengue rapid test kits in Southeast Asia.
• Genetics Generation Advancement: Its AI center has assisted over 30 pharmaceutical plants with electronic regulatory filings across 11 countries. It has also established a landmark clinical exosome database in collaboration with the MOHW.
• Kimforest & AmCAD: Kimforest is partnering with Illumina to deploy multi-omics technologies across the Asia-Pacific. AmCAD has signed an exclusive deal with a Turkish distributor for its FDA-cleared "AmCAD-UO" sleep apnea detection system, securing its first major batch order.

Resource: 生技業者 搶攻海外防疫商機